[go: up one dir, main page]

MX2007002532A - Metodos para el tratamiento de enfermedades proliferativas de la piel utilizando derivados de carbazol. - Google Patents

Metodos para el tratamiento de enfermedades proliferativas de la piel utilizando derivados de carbazol.

Info

Publication number
MX2007002532A
MX2007002532A MX2007002532A MX2007002532A MX2007002532A MX 2007002532 A MX2007002532 A MX 2007002532A MX 2007002532 A MX2007002532 A MX 2007002532A MX 2007002532 A MX2007002532 A MX 2007002532A MX 2007002532 A MX2007002532 A MX 2007002532A
Authority
MX
Mexico
Prior art keywords
methods
skin diseases
proliferative skin
carbazole derivatives
treating proliferative
Prior art date
Application number
MX2007002532A
Other languages
English (en)
Inventor
Robert L Hudkins
Samuel R Denmeade
Original Assignee
Cephalon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cephalon Inc filed Critical Cephalon Inc
Publication of MX2007002532A publication Critical patent/MX2007002532A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invencion se refiere a un metodo para tratar una enfermedad proliferativa de la piel, que comprende administrar una cantidad terapeuticamente efectiva de un inhibidor de trk.
MX2007002532A 2004-09-10 2005-09-09 Metodos para el tratamiento de enfermedades proliferativas de la piel utilizando derivados de carbazol. MX2007002532A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US60920304P 2004-09-10 2004-09-10
US11/222,409 US20060058250A1 (en) 2004-09-10 2005-09-08 Methods of treating proliferative skin diseases using carbazole derivatives
PCT/US2005/032489 WO2006031772A1 (en) 2004-09-10 2005-09-09 Methods of treating proliferative skin diseases using carbazole derivatives

Publications (1)

Publication Number Publication Date
MX2007002532A true MX2007002532A (es) 2007-05-09

Family

ID=36034857

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007002532A MX2007002532A (es) 2004-09-10 2005-09-09 Metodos para el tratamiento de enfermedades proliferativas de la piel utilizando derivados de carbazol.

Country Status (14)

Country Link
US (1) US20060058250A1 (es)
EP (1) EP1786418A1 (es)
JP (1) JP2008512497A (es)
KR (1) KR20070113186A (es)
AR (1) AR050930A1 (es)
AU (1) AU2005285007A1 (es)
BR (1) BRPI0515115A (es)
CA (1) CA2577024A1 (es)
IL (1) IL181003A0 (es)
MX (1) MX2007002532A (es)
MY (1) MY156431A (es)
NO (1) NO20071052L (es)
TW (1) TW200621266A (es)
WO (1) WO2006031772A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR114110A1 (es) 2018-02-28 2020-07-22 Lilly Co Eli Anticuerpo anti-trka
WO2021138391A1 (en) 2019-12-30 2021-07-08 Tyra Biosciences, Inc. Indazole compounds

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5705511A (en) * 1994-10-14 1998-01-06 Cephalon, Inc. Fused pyrrolocarbazoles
JP4405667B2 (ja) * 1997-12-31 2010-01-27 セフアロン・インコーポレーテツド Ｋ−２５２ａの３’−エピマー誘導体
US6127401A (en) * 1998-06-05 2000-10-03 Cephalon, Inc. Bridged indenopyrrolocarbazoles
US6013646A (en) * 1998-07-02 2000-01-11 Bayer Corporation Indolocarbazole derivatives useful for the treatment of neurodegenerative diseases and cancer
US6841567B1 (en) * 1999-02-12 2005-01-11 Cephalon, Inc. Cyclic substituted fused pyrrolocarbazoles and isoindolones
US6399780B1 (en) * 1999-08-20 2002-06-04 Cephalon, Inc. Isomeric fused pyrrolocarbazoles and isoindolones
CZ2003680A3 (cs) * 2000-08-11 2003-11-12 Cephalon, Inc. Způsob modulace kinasových proteinů s vícenásobnou vazbou a vyhledávání sloučenin modulujících kinasové proteiny s vícenásobnou vazbou
US6667173B2 (en) * 2000-12-01 2003-12-23 The Schepens Eye Research Institute Nucleic acids encoding platelet derived growth factor-alpha receptors
US7241779B2 (en) * 2003-12-23 2007-07-10 Cephalon, Inc. Fused pyrrolocarbazoles

Also Published As

Publication number Publication date
JP2008512497A (ja) 2008-04-24
CA2577024A1 (en) 2006-03-23
MY156431A (en) 2016-02-26
NO20071052L (no) 2007-04-03
US20060058250A1 (en) 2006-03-16
TW200621266A (en) 2006-07-01
WO2006031772A1 (en) 2006-03-23
EP1786418A1 (en) 2007-05-23
AU2005285007A1 (en) 2006-03-23
AR050930A1 (es) 2006-12-06
BRPI0515115A (pt) 2008-07-01
KR20070113186A (ko) 2007-11-28
IL181003A0 (en) 2007-07-04

Similar Documents

Publication Publication Date Title
EA200501849A1 (ru) Производные пиразолохиназолина: способ получения и применение в качестве ингибиторов киназ
NO2017019I2 (no) Enzalutamid eller et farmasøytisk akseptabelt salt derav
NO20083002L (no) Fremgangsmate for anvendelse av CD40-bindende forbindelser
NO20074999L (no) Metode og preparat for behandling av perifere vaskulaere sykdommer
EA200870193A1 (ru) Цитотоксические агенты, включающие новые производные томаймицина, и их терапевтическое применение
EA200970611A1 (ru) Замещенные пиразолохиназолиновые производные, способ их получения и их применение в качестве ингибиторов киназы
UA94097C2 (ru) Пиридил- и пиримидинилзамещенные производной пиррола, тиофена и фурана как ингибиторы киназ
WO2008031551A3 (en) Non-neuroendocrine cancer therapy
AU5584901A (en) Use of cyclic gmp-specific phosphodiesterase inhibitors for treatment of parkinson's disease
GEP20084551B (en) 4-phenylamino-quinazolin-6-yl-amides
ZA200810113B (en) Method for the treatment and prevention of ocular disorders
MX346186B (es) Inhibidores de proteina cinasas.
EA200700851A1 (ru) Получение и применение бифенил-4-илкарбониламинокислотных производных для лечения ожирения
EA201101507A1 (ru) Способы лечения солидных опухолей
MX374396B (es) Rocio de fentanilo sublingual.
AR072442A1 (es) Metodo para la terapia del cancer, uso, kit
TN2009000444A1 (en) Combination therapy with a compound acting as a plateletadp receptor inhibitor
MX2012002758A (es) Pirazinil-piridinas utiles para el tratamiento de enfermedades proliferativas.
TN2011000227A1 (en) Method for treating or preventing thrombosis using dabigatran etexilate or a salt thereof with improved efficacy over conventional warfarin therapy
AU2010279892A8 (en) Humanized anti-amyloid-b oligomer antibody
IL162384A0 (en) Composition inhibiting matrix-metallproteinases for the treatment of neoplastic diseases
UA97348C2 (en) HETEROCYCLIC NF-kB INHIBITORS
TW200612922A (en) Inhibitors of hsp90
MX2022006052A (es) Inhibidores de la caspasa 6 y usos de los mismos.
MX2007002532A (es) Metodos para el tratamiento de enfermedades proliferativas de la piel utilizando derivados de carbazol.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal